2010 – 2016  

Senior physician, Institute for Clinical Chemistry and Clinical Pharmacology (IKCKP), University Hospital Bonn (UKB)

2007 – 2010      

Head of the Paediatric Laboratory of the Dr. von Hauner’schen Children’s Hospital, Deputy Head of the Inner City Central Laboratory of the LMU Munich

2008      

Specialist in laboratory medicine

1999 – 2006

Further training in clinical chemistry, haematology and immunology at the Institute for Clinical Chemistry, University Hospital of the LMU Munich; microbiology, transfusion medicine and internal medicine at the specialist lung hospitals in Gauting

1999 – 2006      

Research associate at the Competence Centre “Oncological Laboratory Diagnostics”, LMU Munich

1996 – 2004 

Clinical-experimental dissertation, LMU Munich

1991 – 1999 

Study of human medicine, LMU Munich

2020     

apl. professorship, TU Munich

2014 

apl. professorship, University of Bonn

2006   

Post-doctoral qualification in laboratory medicine, LMU Munich

Patents EP 1064549, US 7229772, US 7759071, WO 2014/131845

2004

Doctoral Award of the Munich University Society

2004   

Doctorate in Human Medicine, LMU Munich (summa cum laude)

“Nucleosomes as cell death parameters in patients with malignant tumours”.

1992 – 1996

Scholarship “Studienstiftung Cusanuswerk”

International

Since 2021  

Member of the WHO-IARC Collaboration for Cancer Classification and Research (IC3R) Steering Committee

2019 – 2021 

Vice-President Germany of CESAR

Since 2017 

Head of the Section “Translational Research” of CESAR

Since 2013

Secretary of the International Society of Oncology & BioMarkers (ISOBM)

National

Since 2021

Deputy Spokesperson of the “Molecular Diagnostics” Competence Field of the DGKL

Since 2020     

Representative of the DGKL in the specialist group D 5 of the German Medical Association: “Molecular genetic and cytogenetic investigations”.

Since 2020     

Task Force “Serological COVID-19 Testing” of the DGKL

Since 2017 

Guideline Committee of the DGKL: “Oncology/ Molecular Diagnostics”

Since 2014    

Ring test leader for tumour markers at Instand e.V.

• European Society of Cardiology (ESC)
• International Society of Oncological BioMarkers (ISOBM)
• WHO-IARC Collaboration for Cancer Classification and Research (IC3R)
• Central European Society for Anticancer Drug Research (CESAR)
• German Society of Extracellular Vesicles (GSEV)
• German Society for Clinical Chemistry and Laboratory Medicine (DGKL)
• Society for the Promotion of Quality Assurance in Medical Laboratories (INSTAND e.V.)
• Institut für Qualitätsmanagement in Medizinischen Laboratorien e.V. (INQUAM e.V.)

Editorial Board, Associate Editor at scientific journals

Journal of Laboratory Medicine / Laboratoriumsmedizin: Oncology Section, Liquid Profiling

Diagnostics

Tumour Biology

BMC Cancer

Trillium Diagnostics

Editor for special editions

J Lab Med

“Liquid Profiling – Circulating Nucleic Acid Diagnostics” (2021)

Diagnostics

“Cell-free nucleic acids – New insights into physico-chemical properties, analytical considerations, and clinical applications” (2021)

J Lab Med

“Blood-based Nucleic Acid Diagnostic” (2016)

Cancer Biomarkers

“Lung Cancer Biomarkers (2010)

Organisation of scientific congresses

MEDICA

LabMed Forum: Cardiology, Oncology, Young Scientists Day (since 2017)

Trillium Academy

Onco-Symposium Munich (since 2019)

CNAPS

Symposium on “Circulating Nucleic Acids in Plasma and Serum” (2015)

ISOBM

Annual Conferences of the International Society of Oncology &     BioMarkers (ISOBM, since 2016)

Original works 

175 (first/senior 74)

Reviews 

82 (first/senior 58)

H-index

51 (since 2016:   38)

i10 index  

137 (since 2016: 111)

Citations 

9696 (since 2016:   5617)

cum. IF     

736.7

(citation details and indices according to Google Scholar, 01 October, 2021)

Selected publications

1.  Palm J, Holdenrieder S, Hoffmann G, Klawonn F, Hörer J, Ewert P. Age-adjusted NT-proBNP predicts cardiovascular events in children. J Am Coll Cardiol, 2021; in press
2.  Cavalier E, Guiot J, Lechner K, Dutsch A, Eccleston M, Herzog M, Schomburg A, Kelly T, Holdenrieder S. Circulating nucleosomes as potential prognostic markers for COVID-19 disease severity. Front Mol Biosci 2021; 8: 600881.
3.  König KC, Lahm H, Dressen M, Doppler S, Eichhorn S, Beck N, Kraehschuetz K, Doll S, Mann M, Holdenrieder S, Lange R, Krane M. Aggrecan – a new biomarker for acute type A aortic dissection. Sci Rep 2021; 11: 10371.
4.  Ungerer V, Bronkhorst AJ, van den Ackerveken P, Herzog M, Holdenrieder S. Serial profiling of cell-free DNA and nucleosome histone modifications in three cell lines. Sci Rep 2021; 11: 9460.
5.  Bronkhorst AJ, Ungerer V, Diehl F, Anker P, Dor Y, Fleischhacker M, Gahan PB, Hui L, Holdenrieder S, Thierry A. Towards systematic nomenclature for cell-free DNA. Hum Genet. 2020 Oct 29. doi: 10.1007/s00439-020-02227-2
6.  Völker-Albert M, Bronkhorst A, Holdenrieder S, Imhof A. Histone modifications in stem cell development and their clinical implications. Stem Cell Reports 2020; 15: 1196-1205.
7.  Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M, Walter M, Wenzel F, Wölfel R, Renz H; COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). SARS-CoV-2 Antibody Testing – Questions to be asked. J Allergy Clin Immunol. 2020: S0091-6749(20)30739-9.
8.  Ungerer V, Bronkhorst AJ, Holdenrieder S. Preanalytical variables that affect the outcome of cell-free DNA measurements. Crit Rev Clin Lab Sci; 2020; May 12:1-24.
9.  Bronkhorst AJ, Ungerer V, Holdenrieder S. Early detection of cancer using circulating tumour DNA: biological, physiological and analytical considerations. Crit Rev Clin Lab Sci 2019; Dec 22: 1-17.
10.  Lahm H, Dreßen M, Beck N, Doppler W, Deutsch MA, Matsushima S, Neb I, König KC, Sideris K, Voss S, Eschenbach L, Puluca N, Deisenhofer I, Doll S, Holdenrieder S, Mann M, Lange R, Krane M. Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage. Sci Rep 2019; 9: 9986.
11.  Kipfmueller F, Heindel K, Geipel A, Berg C, Bartmann P, Reutter H, Mueller A, Holdenrieder S. Expression of soluble receptor for advanced glycation end products (sRAGE) is associated with disease severity in congenital diaphragmatic hernia. Am J Physiol Lung Cell Mol Physiol 2019; published online
12.  Kruger S, Nagel D, Ormanns S, Liebmann S, Kirchner T, Ross C, Diehl F, Westphalen CB, Haas M, Heinemann V, Boeck S, Holdenrieder S. Repeated mutKRAS ctDNA measurements in advanced pancreatic cancer patients: kinetics, response prediction and therapy monitoring in comparison to protein based tumour markers. Ann Oncol 2018; 29: 2348-2355.
13.  Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) for the assessment of therapy response in non-small-cell lung cancer: a systematic review and meta-analysis. Br J Cancer 2017; 116: 1037-1045.
14.  Korse CM, Holdenrieder S, Zhi X, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Mu H, Molina R. Multicenter Evaluation of a New Progastrin-Releasing Peptide (ProGRP) Immunoassay across Europe and China. Clin Chim Acta 2015; 438: 388-95.
15.  Holdenrieder S. Circulating nucleic acids in therapy monitoring. In P.B. Gahan (ed.), Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring, Advances in Predictive, Preventive and Personalised Medicine 5, Springer, 2014: 309-348.
16.  Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 2013; 133: 2619-30.
17.  Boeck S, Wittwer C, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Brit J Cancer 2013; 108: 1684-94.
18.  Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010; 16: 887-96.
19.  Holdenrieder S, v Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008; 14: 7813-21.
20.  Holdenrieder S, Stieber P, v Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced NSCLC. Clin Cancer Res 2004; 10: 5981-7.